For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 1,849,996 | |||
| Sales and marketing | 189,470 | |||
| General and administrative | 3,723,635 | |||
| Total operating expenses | 5,763,101 | |||
| Operating loss | -5,763,101 | |||
| Other income | 71,224 | |||
| Digital asset staking compensation | 5,121 | |||
| Change in fair value of digital assets | -995,161 | |||
| Warrant expense | 665,030 | |||
| Changes in fair value of warrant liability | -319,537 | |||
| Total other expenses | -1,264,309 | |||
| Loss from operations before income taxes | -7,027,410 | |||
| Net loss | -7,027,410 | |||
| Basic EPS | -8.93 | |||
| Diluted EPS | -8.93 | |||
| Basic Average Shares | 787,020 | |||
| Diluted Average Shares | 787,020 | |||
ENDRA Life Sciences Inc. (NDRA)
ENDRA Life Sciences Inc. (NDRA)